JANX JANUX THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, JANUX THERAPEUTICS INC reported revenue of $10.3M, net income of −$22.0M and diluted EPS of −$0.35; over the last four quarters revenue was $24.0M and net income −$103M; for the fiscal year ended December 2025 revenue was $10.0M, down 5.6% on the year before.

JANX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $10.0M, gross profit n/a, operating income −$158M, net income −$114M (margin -1136.3%), EPS −$1.83
• Fiscal year ended Dec 2024: revenue $10.6M, gross profit n/a, operating income −$98.8M, net income −$69.0M (margin -651.6%), EPS −$1.28
• Fiscal year ended Dec 2023: revenue $8.08M, gross profit n/a, operating income −$73.0M, net income −$58.3M (margin -721.2%), EPS −$1.32
• Fiscal year ended Dec 2022: revenue $8.61M, gross profit n/a, operating income −$67.1M, net income −$63.1M (margin -732.2%), EPS −$1.52
• Fiscal year ended Dec 2021: revenue $3.64M, gross profit n/a, operating income −$32.9M, net income −$32.7M (margin -898.3%), EPS −$1.39

JANX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $10.3M, net income −$22.0M, EPS −$0.35
• Quarter ended Mar 31, 2026: revenue $3.73M, net income −$24.4M, EPS −$0.39
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$31.9M, EPS −$0.51
• Quarter ended Sep 30, 2025: revenue $10.0M (up 2177.9% year over year), net income −$24.3M, EPS −$0.39
• Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$33.9M, EPS −$0.55
• Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$23.5M, EPS −$0.38
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$20.2M, EPS −$0.36
• Quarter ended Sep 30, 2024: revenue $439K (down 82.6% year over year), net income −$28.1M, EPS −$0.51
• Quarter ended Jun 30, 2024: revenue $8.90M (up 741.7% year over year), net income −$5.96M, EPS −$0.11
• Quarter ended Mar 31, 2024: revenue $1.25M (down 38.9% year over year), net income −$14.8M, EPS −$0.30
• Quarter ended Dec 31, 2023 (from the annual report): revenue $2.46M (down 13.5% year over year), net income −$11.8M, EPS −$0.23
• Quarter ended Sep 30, 2023: revenue $2.52M (up 38.8% year over year), net income −$11.6M, EPS −$0.25
• Quarter ended Jun 30, 2023: revenue $1.06M (down 55.3% year over year), net income −$17.5M, EPS −$0.42
• Quarter ended Mar 31, 2023: revenue $2.05M (up 28.9% year over year), net income −$17.5M, EPS −$0.42
• Quarter ended Dec 31, 2022 (from the annual report): revenue $2.85M (up 76.1% year over year), net income −$16.1M, EPS −$0.39
• Quarter ended Sep 30, 2022: revenue $1.81M (up 56.4% year over year), net income −$16.7M, EPS −$0.40
• Quarter ended Jun 30, 2022: revenue $2.37M (up 390.7% year over year), net income −$16.9M, EPS −$0.41
• Quarter ended Mar 31, 2022: revenue $1.59M (up 318.2% year over year), net income −$13.4M, EPS −$0.32
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.62M, net income −$13.4M, EPS $1.55
• Quarter ended Sep 30, 2021: revenue $1.16M, net income −$10.8M, EPS −$0.26

JANX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$82.2M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$43.8M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$50.6M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$42.9M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$17.0M, share buybacks n/a

JANX balance sheet

• Jun 30, 2026: cash $27.8M, total assets $1.01B, total liabilities $79.7M, shareholders' equity $928M
• Mar 31, 2026: cash $51.8M, total assets $1.03B, total liabilities $86.7M, shareholders' equity $942M
• Dec 31, 2025: cash $52.3M, total assets $1.00B, total liabilities $44.7M, shareholders' equity $957M
• Sep 30, 2025: cash $48.4M, total assets $1.02B, total liabilities $48.2M, shareholders' equity $977M
• Jun 30, 2025: cash $52.4M, total assets $1.03B, total liabilities $41.7M, shareholders' equity $991M
• Mar 31, 2025: cash $73.7M, total assets $1.05B, total liabilities $38.3M, shareholders' equity $1.01B
• Dec 31, 2024: cash $431M, total assets $1.06B, total liabilities $38.7M, shareholders' equity $1.02B
• Sep 30, 2024: cash $26.8M, total assets $695M, total liabilities $38.9M, shareholders' equity $656M

What is JANX's revenue?

JANUX THERAPEUTICS INC reported $24.0M of revenue over its last four quarters, through June 30, 2026.

Is JANX profitable?

No. JANUX THERAPEUTICS INC lost $103M over the last four quarters.

What is JANX's EPS?

Diluted earnings per share over the last four quarters were −$1.64; −$0.35 in the latest quarter.

JANX ownership and insider trades · All stocks